Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Weygant, Nathaniel ^a   Qu, Dongfeng ^a,b   Berry, William L ^a,c   May, Randal ^a,b   Chandrakesan, Parthasarathy ^a   Owen, Daniel B ^a   Sureban, Sripathi M ^a,b   Ali, Naushad ^a,b,c   Janknecht, Ralf ^a,c   Houchen, Courtney W ^a,b,c,d  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Peggy and Charles Stephenson Oklahoma Cancer Institute   (United States)

^d Department of Cell Biology University of Oklahoma Health Sciences Center ^*  (United States)

Author keywords

DCLK1; Kinase inhibitor; LRRK2 IN 1; Small molecule inhibitor; Tumor stem cell

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; DOUBLECORTIN; DOUBLECORTIN LIKE KINASE 1; LRRK 2IN 1; MICRORNA 145; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MYC PROTEIN; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN BCL 2; UNCLASSIFIED DRUG; BENZODIAZEPINE DERIVATIVE; COLLAGEN; DCLK1 PROTEIN, HUMAN; DRUG COMBINATION; ISOENZYME; LAMININ; LRRK2-IN1; MATRIGEL; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEOGLYCAN; PYRIMIDINE DERIVATIVE; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SIZE; CELL DEATH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE C MYC; OVERALL SURVIVAL; PANCREAS CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BINDING SITE; CELL MOTION; CELL SURVIVAL; CHEMISTRY; DIFFUSION CHAMBER; DRUG COMBINATION; DRUG EFFECTS; GENE VECTOR; GENETICS; LENTIVIRINAE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BENZODIAZEPINONES; BINDING SITES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; COLLAGEN; DIFFUSION CHAMBERS, CULTURE; DRUG COMBINATIONS; GENE EXPRESSION; GENETIC VECTORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOENZYMES; LAMININ; LENTIVIRUS; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEOGLYCANS; PYRIMIDINES;

EID: 84901279099     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-103     Document Type: Article

References (55)

1. Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, DEmilio A, Stagno F, le Coutre P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jang E, Reiffers J, Valsecchi MG, Kim DW. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011, 103:553-561. 10.1093/jnci/djr060, 21422402.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, . Sharp Investigators Study Group Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390. 10.1056/NEJMoa0708857, 18650514, Sharp Investigators Study Group.
3. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957. 10.1056/NEJMoa0810699, 19692680.
4. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009, 9:28-39. 10.1038/nrc2559, 19104514.
5. May R, Riehl TE, Hunt C, Sureban SM, Anant S, Houchen CW. Identification of a novel putative gastrointestinal stem cell and adenoma stem cell marker, doublecortin and CaM kinase-like-1, following radiation injury and in adenomatous polyposis coli/multiple intestinal neoplasia mice. Stem Cells 2008, 26:630-637. 10.1634/stemcells.2007-0621, 18055444.
6. May R, Sureban SM, Lightfoot SA, Hoskins AB, Brackett DJ, Postier RG, Ramanujam R, Rao CV, Wyche JH, Anant S, Houchen CW. Identification of a novel putative pancreatic stem/progenitor cell marker DCAMKL-1 in normal mouse pancreas. Am J Physiol Gastrointest Liver Physiol 2010, 299:G303-G310. 10.1152/ajpgi.00146.2010, 2928534, 20522640.
7. Sureban SM, May R, Ramalingam S, Subramaniam D, Natarajan G, Anant S, Houchen CW. Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanism. Gastroenterology 2009, 137:649-659. 659 e641-642, 10.1053/j.gastro.2009.05.004, 2775069, 19445940.
8. Sureban SM, May R, Lightfoot SA, Hoskins AB, Lerner M, Brackett DJ, Postier RG, Ramanujam R, Mohammed A, Rao CV, Wyche JH, Anant S, Houchen CW. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res 2011, 71:2328-2338. 10.1158/0008-5472.CAN-10-2738, 3072762, 21285251.
9. Bailey JM, Alsina J, Rasheed ZA, McAllister FM, Fu YY, Plentz R, Zhang H, Pasricha PJ, Bardeesy N, Matsui W, Maitra A, Leach SD. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in pre-invasive pancreatic cancer. Gastroenterology 2013, 146:245-256.
10. Gerbe F, van Es JH, Makrini L, Brulin B, Mellitzer G, Robine S, Romagnolo B, Shroyer NF, Bourgaux JF, Pignodel C, Clevers H, Jay P. Distinct ATOH1 and Neurog3 requirements define tuft cells as a new secretory cell type in the intestinal epithelium. J Cell Biol 2011, 192:767-780. 10.1083/jcb.201010127, 3051826, 21383077.
11. Nakanishi Y, Seno H, Fukuoka A, Ueo T, Yamaga Y, Maruno T, Nakanishi N, Kanda K, Komekado H, Kawada M, Isomura A, Kawada K, Sakai Y, Yanagita M, Kageyama R, Kawaguchi Y, Taketo MM, Yonehara S, Chiba T. Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nat Genet 2012, 45:98-103. 10.1038/ng.2481, 23202126.
12. Verissimo CS, Molenaar JJ, Meerman J, Puigvert JC, Lamers F, Koster J, Danen EH, van de Water B, Versteeg R, Fitzsimons CP, Vreugdenhil E. Silencing of the microtubule-associated proteins doublecortin-like and doublecortin-like kinase-long induces apoptosis in neuroblastoma cells. Endocr Relat Cancer 2010, 17:399-414. 10.1677/ERC-09-0301, 20228126.
13. Verissimo CS, Elands R, Cheng S, Saaltink DJ, Ter Horst JP, Alme MN, Pont C, van de Water B, Havik B, Fitzsimons CP, Vreugdenhil E. Silencing of Doublecortin-Like (DCL) results in decreased mitochondrial activity and delayed neuroblastoma tumor growth. PLoS One 2013, 8:e75752. 10.1371/journal.pone.0075752, 3784435, 24086625.
14. Sureban SM, May R, Mondalek FG, Qu D, Ponnurangam S, Pantazis P, Anant S, Ramanujam RP, Houchen CW. Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. J Nanobiotechnol 2011, 9:40.
15. Sureban SM, May R, Qu D, Weygant N, Chandrakesan P, Ali N, Lightfoot SA, Pantazis P, Rao CV, Postier RG, Houchen CW. DCLK1 Regulates Pluripotency and Angiogenic Factors via microRNA-Dependent Mechanisms in Pancreatic Cancer. PLoS One 2013, 8:e73940. 10.1371/journal.pone.0073940, 3767662, 24040120.
16. Liu GH, Qu J, Suzuki K, Nivet E, Li M, Montserrat N, Yi F, Xu X, Ruiz S, Zhang W, Wagner U, Kim A, Ren B, Li Y, Goebl A, Kim J, Soligalla RD, Dubova I, Thompson J, Yates J, Esteban CR, Sancho-Martinez I, Izpisua Belmonte JC. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 2012, 491:603-607. 10.1038/nature11557, 3504651, 23075850.
17. Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, Lee JD, Patricelli MP, Nomanbhoy TK, Alessi DR, Gray NS. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol 2011, 7:203-205. 10.1038/nchembio.538, 3287420, 21378983.
18. Thu KL, Radulovich N, Becker-Santos DD, Pikor LA, Pusic A, Lockwood WW, Lam WL, Tsao MS. SOX15 is a candidate tumor suppressor in pancreatic cancer with a potential role in Wnt/beta-catenin signaling. Oncogene 2014, 33:279-288. 10.1038/onc.2012.595, 23318427.
19. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000, 24:227-235. 10.1038/73432, 10700174.
20. Kantara C, OConnell M, Sarkar S, Moya S, Ullrich R, Singh P. Curcumin Promotes Autophagic Survival of a Sub-Set of Colon Cancer Stem Cells, which are Ablated by DCLK1-siRNA. Cancer Res 2014,
21. Ponnurangam S, Mammen JM, Ramalingam S, He Z, Zhang Y, Umar S, Subramaniam D, Anant S. Honokiol in combination with radiation targets notch signaling to inhibit colon cancer stem cells. Mol Cancer Ther 2012, 11:963-972. 10.1158/1535-7163.MCT-11-0999, 3324630, 22319203.
22. Li L, Bellows CF. Doublecortin-like kinase 1 exhibits cancer stem cell-like characteristics in a human colon cancer cell line. Chin J Cancer Res 2013, 25:134-142. 3626979, 23592893.
23. Duesberg P, Stindl R, Hehlmann R. Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy. Proc Natl Acad Sci U S A 2001, 98:11283-11288. 10.1073/pnas.201398998, 58721, 11553793.
24. Nishimoto S, Nishida E. MAPK signalling: ERK5 versus ERK1/2. EMBO Rep 2006, 7:782-786. 10.1038/sj.embor.7400755, 1525153, 16880823.
25. Watanabe K, Akimoto Y, Yugi K, Uda S, Chung J, Nakamuta S, Kaibuchi K, Kuroda S. Latent process genes for cell differentiation are common decoders of neurite extension length. J Cell Sci 2012, 125:2198-2211. 10.1242/jcs.097709, 22344266.
26. Leushacke M, Sporle R, Bernemann C, Brouwer-Lehmitz A, Fritzmann J, Theis M, Buchholz F, Herrmann BG, Morkel M. An RNA interference phenotypic screen identifies a role for FGF signals in colon cancer progression. PLoS One 2011, 6:e23381. 10.1371/journal.pone.0023381, 3154943, 21853123.
27. Jurchott K, Kuban RJ, Krech T, Bluthgen N, Stein U, Walther W, Friese C, Kielbasa SM, Ungethum U, Lund P, Knosel T, Kemmner W, Morkel M, Fritzmann J, Schlag PM, Birchmeier W, Krueger T, Sperling S, Sers C, Royer HD, Herzel H, Schafer R. Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS Genet 2010, 6:e1001231. 10.1371/journal.pgen.1001231, 2996331, 21170361.
28. Itzkovitz S, Lyubimova A, Blat IC, Maynard M, van Es J, Lees J, Jacks T, Clevers H, van Oudenaarden A. Single-molecule transcript counting of stem-cell markers in the mouse intestine. Nat Cell Biol 2012, 14:106-114.
29. Van Landeghem L, Santoro MA, Krebs AE, Mah AT, Dehmer JJ, Gracz AD, Scull BP, McNaughton K, Magness ST, Lund PK. Activation of two distinct Sox9-EGFP-expressing intestinal stem cell populations during crypt regeneration after irradiation. Am J Physiol Gastrointest Liver Physiol 2012, 302:G1111-G1132. 10.1152/ajpgi.00519.2011, 3362093, 22361729.
30. May R, Qu D, Weygant N, Chandrakesan P, Ali N, Lightfoot SA, Li L, Sureban SM, Houchen CW. Dclk1 deletion in tuft cells results in impaired epithelial repair after radiation injury. Stem Cells 2013,
31. Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, van de Wetering M, Clevers H. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012, 337:730-735. 10.1126/science.1224676, 22855427.
32. Proctor E, Waghray M, Lee CJ, Heidt DG, Yalamanchili M, Li C, Bednar F, Simeone DM. Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma. PLoS One 2013, 8:e55820. 10.1371/journal.pone.0055820, 3577834, 23437065.
33. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, Yan H, Wang W, Chen S, Viale A, Zheng H, Paik JH, Lim C, Guimaraes AR, Martin ES, Chang J, Hezel AF, Perry SR, Hu J, Gan B, Xiao Y, Asara JM, Weissleder R, Wang YA, Chin L, Cantley LC, DePinho RA. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012, 149:656-670. 10.1016/j.cell.2012.01.058, 3472002, 22541435.
34. Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM, Potter JD, Newcomb PA. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer 2013, 108:1757-1764. 10.1038/bjc.2013.118, 3668469, 23511557.
35. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ. EMT and dissemination precede pancreatic tumor formation. Cell 2012, 148:349-361. 10.1016/j.cell.2011.11.025, 3266542, 22265420.
36. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011, 331:1559-1564. 10.1126/science.1203543, 21436443.
37. Valenta T, Hausmann G, Basler K. The many faces and functions of beta-catenin. EMBO J 2012, 31:2714-2736. 10.1038/emboj.2012.150, 3380220, 22617422.
38. Sanchez-Tillo E, de Barrios O, Siles L, Cuatrecasas M, Castells A, Postigo A. beta-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci U S A 2011, 108:19204-19209. 10.1073/pnas.1108977108, 3228467, 22080605.
39. Cancer Genome Atlas N Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337. 10.1038/nature11252, 3401966, 22810696, Cancer Genome Atlas N.
40. Shimomura S, Nagamine T, Nimura T, Sueyoshi N, Shigeri Y, Kameshita I. Expression, characterization, and gene knockdown of zebrafish doublecortin-like protein kinase. Arch Biochem Biophys 2007, 463:218-230. 10.1016/j.abb.2007.03.036, 17498644.
41. Lin PT, Gleeson JG, Corbo JC, Flanagan L, Walsh CA. DCAMKL1 encodes a protein kinase with homology to doublecortin that regulates microtubule polymerization. J Neurosci 2000, 20:9152-9161.
42. Nagamine T, Shimomura S, Sueyoshi N, Kameshita I. Influence of Ser/Pro-rich domain and kinase domain of double cortin-like protein kinase on microtubule-binding activity. J Biochem 2011, 149:619-627. 10.1093/jb/mvr013, 21278387.
43. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011, 29:1046-1051. 10.1038/nbt.1990, 22037378.
44. Wacker SA, Houghtaling BR, Elemento O, Kapoor TM. Using transcriptome sequencing to identify mechanisms of drug action and resistance. Nat Chem Biol 2012, 8:235-237. 10.1038/nchembio.779, 3281560, 22327403.
45. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007, 26:3279-3290. 10.1038/sj.onc.1210421, 17496922.
46. Kuribara M, Jenks BG, Dijkmans TF, de Gouw D, Ouwens DT, Roubos EW, Vreugdenhil E, Scheenen WJ. ERK-regulated double cortin-like kinase (DCLK)-short phosphorylation and nuclear translocation stimulate POMC gene expression in endocrine melanotrope cells. Endocrinology 2011, 152:2321-2329. 10.1210/en.2011-0067, 21447633.
47. Miyamoto-Sato E, Fujimori S, Ishizaka M, Hirai N, Masuoka K, Saito R, Ozawa Y, Hino K, Washio T, Tomita M, Yamashita T, Oshikubo T, Akasaka H, Sugiyama J, Matsumoto Y, Yanagawa H. A comprehensive resource of interacting protein regions for refining human transcription factor networks. PLoS One 2010, 5:e9289. 10.1371/journal.pone.0009289, 2827538, 20195357.
48. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 2004, 25:1605-1612. 10.1002/jcc.20084, 15264254.
49. Yang Y, Faraggi E, Zhao H, Zhou Y. Improving protein fold recognition and template-based modeling by employing probabilistic-based matching between predicted one-dimensional structural properties of query and corresponding native properties of templates. Bioinformatics 2011, 27:2076-2082. 10.1093/bioinformatics/btr350, 3137224, 21666270.
50. Schneidman-Duhovny D, Inbar Y, Polak V, Shatsky M, Halperin I, Benyamini H, Barzilai A, Dror O, Haspel N, Nussinov R, Wolfson HJ. Taking geometry to its edge: fast unbound rigid (and hinge-bent) docking. Proteins 2003, 52:107-112. 10.1002/prot.10397, 12784375.
51. Laskowski RA, Swindells MB. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 2011, 51:2778-2786. 10.1021/ci200227u, 21919503.
52. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res 2003, 31:3381-3385. 10.1093/nar/gkg520, 168927, 12824332.
53. Chang L-J, Zaiss A-K. Lentiviral vectors preparation and use. Gene Therapy Protocols, Volume 69 2002, 303-318. New York: Springer, Morgan J, Methods in Molecular Medicine.
54. Wang H, Wang F, Tao X, Cheng H. Ammonia-containing dimethyl sulfoxide: an improved solvent for the dissolution of formazan crystals in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Anal Biochem 2012, 421:324-326. 10.1016/j.ab.2011.10.043, 22100715.
55. Rouwette TP, Kozicz T, Olde Loohuis NF, Gaszner B, Vreugdenhil E, Scheffer GJ, Roubos EW, Vissers KC, Scheenen WJ. Acute pain increases phosphorylation of DCLK-long in the Edinger-Westphal nucleus but not in the hypothalamic paraventricular nucleus of the rat. J Pain 2010, 11:930-940. 10.1016/j.jpain.2009.12.017, 20418180.